Home › Companies › Y-mAbs Therapeutics, Inc. › 2025-2026

Y-mAbs Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Y-mAbs Therapeutics, Inc.’s Form 8-K, filed July 15, 2025 (Item 5.07 on EDGAR). Page generated October 18, 2026.

3Ballot items
127Asset managers
488Fund votes
July 11, 2025Meeting date

Results at a glance

Meeting of July 11, 2025: 3 items on Y-mAbs Therapeutics, Inc.’s Form 8-K, filed July 15, 2025: 2 approved · 1 without a stated outcome.

Material dissent

Elect Director: David N. Gill 61% of votes cast Outcome not stated Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2025-2026

Explore Y-mAbs Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Y-mAbs Therapeutics, Inc.

These tallies are Y-mAbs Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed July 15, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Y-mAbs Therapeutics, Inc. — official shareholder meeting results, meeting held July 11, 2025
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: David N. Gill	18,926,572	--	--	11,924,775	3,133,377	61%	Not verified	—
2. Ratification of the Appointment of the Independent Registered Public Accounting Firm	32,884,437	1,097,151	3,136	--	--	97%	Approved	—
3. Advisory Vote on the Compensation of the Named Executive Officers	27,011,027	3,838,565	1,755	--	3,133,377	88%	Approved	—

Source: Y-mAbs Therapeutics, Inc., Form 8-K, filed with the SEC on July 15, 2025 — read the filing on EDGAR.

How asset managers voted at the Y-mAbs Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 127 asset managers that disclosed a Y-mAbs Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: David N. Gill

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

61% Majority: yes · of votes cast

FOR 61%WITHHELD

FOR: 18,926,572WITHHELD: 11,924,775

Details: description as filed, official tally, votes by 48 asset managers

Description as filed by funds: ELECTION OF CLASS I DIRECTOR: DAVID N. GILL

Y-mAbs Therapeutics, Inc.’s own tally for this item (“Elect Director: David N. Gill”): 18,926,572 for, 11,924,775 withheld, per its Form 8-K filed July 15, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 61% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 4,263,209 for, 654,760 withheld.

FOR

FOR: 4,263,209WITHHOLD: 654,760

Largest asset managers voting on “ELECTION OF CLASS I DIRECTOR: DAVID N. GILL” at Y-mAbs Therapeutics, Inc., 2025-2026
Asset manager	For	Withheld	Vote
Vanguard	1,882,029	0	For
BlackRock	1,331,865	0	For
Fidelity	517,346	0	For
Charles Schwab	279,183	0	For
Dimensional	0	234,022	Withhold
Federated Hermes	101,334	0	For
Equitable	46,936	34,620	Mixed
Goldman Sachs	0	55,809	Withhold
TIAA	50,320	0	For
ETFis Series Trust I	0	42,025	Withhold
ALPS ETF Trust	0	31,990	Withhold
Lincoln Financial	0	28,854	Withhold
Northern Trust	0	27,419	Withhold
QUANTITATIVE MASTER SERIES LLC	26,265	0	For
BRIDGEWAY FUNDS INC	0	24,900	Withhold
Global X	0	20,117	Withhold
AIG/SunAmerica	0	18,654	Withhold
PACE SELECT ADVISORS TRUST	0	17,100	Withhold
HC CAPITAL TRUST	0	14,136	Withhold
CLEARWATER INVESTMENT TRUST	0	13,239	Withhold
Brighthouse	0	12,799	Withhold
John Hancock	0	12,203	Withhold
Pacific Life	11,982	0	For
Voya	0	10,211	Withhold
ProShares	0	8,587	Withhold

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

2. 3. Advisory Vote on the Compensation of the Named Executive Officers

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

88% Approved · of votes cast

FOR 88%

FOR: 27,011,027AGAINST: 3,838,565

Details: description as filed, official tally, votes by 127 asset managers

Description as filed by funds: TO APPROVE, ON A NON-BINDING ADVISORY VOTE BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT.

Y-mAbs Therapeutics, Inc.’s own tally for this item (“3. Advisory Vote on the Compensation of the Named Executive Officers”): 27,011,027 for, 3,838,565 against — passed, per its Form 8-K filed July 15, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on the Compensation of the Named Executive Officers The Company's stockholders approved Proposal 3.”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 48 asset managers voting on “TO APPROVE, ON A NON-BINDING ADVISORY VOTE BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS A” at Y-mAbs Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	1,882,029	0	For
BlackRock	1,331,865	0	For
Fidelity	517,346	0	For
Charles Schwab	279,183	0	For
Dimensional	0	234,022	Against
Federated Hermes	101,334	0	For
Equitable	81,556	0	For
Goldman Sachs	55,809	0	For
TIAA	50,320	0	For
ETFis Series Trust I	42,025	0	For
ALPS ETF Trust	31,990	0	For
Lincoln Financial	27,300	1,554	Mixed
Northern Trust	27,419	0	For
QUANTITATIVE MASTER SERIES LLC	26,265	0	For
BRIDGEWAY FUNDS INC	24,900	0	For
Global X	20,117	0	For
AIG/SunAmerica	18,654	0	For
PACE SELECT ADVISORS TRUST	17,100	0	For
HC CAPITAL TRUST	14,136	0	For
CLEARWATER INVESTMENT TRUST	13,239	0	For
Brighthouse	12,799	0	For
John Hancock	12,203	0	For
Pacific Life	11,982	0	For
Voya	10,211	0	For
ProShares	8,587	0	For

Fund voting reports, all 48 managers: 4,668,807 for, 249,162 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 97 asset managers voting on “TO APPROVE, ON A NON-BINDING ADVISORY VOTE BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS A” at Y-mAbs Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Paradigm Biocapital Advisors LP	4,031,230	For
Polar Capital Holdings Plc	3,012,000	For
Caligan Partners LP	2,292,049	For
BlackRock	1,102,177	For
BOOTHBAY FUND MANAGEMENT, LLC	643,133	For
Sofinnova Investments, Inc.	590,000	For
GEODE CAPITAL MANAGEMENT, LLC	583,723	For
State Street	561,870	For
UniSuper Management Pty Ltd	325,000	For
Soleus Capital Management, L.P.	323,618	For
Stonepine Capital Management, LLC	300,000	For
Charles Schwab	279,189	For
DE Shaw	275,747	For
Nantahala Capital Management, LLC	234,722	For
Two Sigma	184,237	For
Citadel	173,950	For
Northern Trust	159,525	For
MELLON INVESTMENTS Corp	114,329	For
JACOBS LEVY EQUITY MANAGEMENT, INC	112,268	For
Federated Hermes	109,063	For
RICE HALL JAMES & ASSOCIATES, LLC	97,864	For
Vanguard	95,554	For
AQR	68,141	For
AllianceBernstein	54,780	For
Nuveen	51,191	For

Institutional-manager reports, all 97 managers: 16,157,961 for, 76,748 against. Showing the 25 largest; see all in the interactive database.

3. 2. Ratification of the Appointment of the Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%

FOR: 32,884,437AGAINST: 1,097,151

Details: description as filed, official tally, votes by 47 asset managers

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.

Y-mAbs Therapeutics, Inc.’s own tally for this item (“2. Ratification of the Appointment of the Independent Registered Public Accounting Firm”): 32,884,437 for, 1,097,151 against — passed, per its Form 8-K filed July 15, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of the Appointment of the Independent Registered Public Accounting Firm The Company's stockholders approved Proposal 2.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 4,903,833 for.

FOR

FOR: 4,903,833

Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm f” at Y-mAbs Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Vanguard	1,882,029	For
BlackRock	1,331,865	For
Fidelity	517,346	For
Charles Schwab	279,183	For
Dimensional	234,022	For
Federated Hermes	101,334	For
Equitable	81,556	For
Goldman Sachs	55,809	For
TIAA	50,320	For
ETFis Series Trust I	42,025	For
ALPS ETF Trust	31,990	For
Lincoln Financial	28,854	For
Northern Trust	27,419	For
QUANTITATIVE MASTER SERIES LLC	26,265	For
BRIDGEWAY FUNDS INC	24,900	For
Global X	20,117	For
AIG/SunAmerica	18,654	For
PACE SELECT ADVISORS TRUST	17,100	For
CLEARWATER INVESTMENT TRUST	13,239	For
Brighthouse	12,799	For
John Hancock	12,203	For
Pacific Life	11,982	For
Voya	10,211	For
ProShares	8,587	For
Jackson National	8,406	For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Largest Y-mAbs Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 43,882,638 shares outstanding at the time of that meeting.

Fund voting reports: top Y-mAbs Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING ADVISORY VOTE BASIS, THE COMPENSATION OF THE COMPANY'S NAMED…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	4.29%
2	BlackRock	3.04%
3	Fidelity	1.18%
4	Charles Schwab	0.64%
5	Dimensional	0.53%
6	Federated Hermes	0.23%
7	Equitable	0.19%
8	Goldman Sachs	0.13%
9	TIAA	0.11%
10	ETFis Series Trust I	0.10%

Institutional-manager reports: top Y-mAbs Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING ADVISORY VOTE BASIS, THE COMPENSATION OF THE COMPANY'S NAMED…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Paradigm Biocapital Advisors LP	9.19%
2	Polar Capital Holdings Plc	6.86%
3	Caligan Partners LP	5.22%
4	BlackRock	2.51%
5	BOOTHBAY FUND MANAGEMENT, LLC	1.47%
6	Sofinnova Investments, Inc.	1.34%
7	GEODE CAPITAL MANAGEMENT, LLC	1.33%
8	State Street	1.28%
9	UniSuper Management Pty Ltd	0.74%
10	Soleus Capital Management, L.P.	0.74%

Reported Y-mAbs Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Y-mAbs Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Johan Wedell‑Wedellsborg	10.75%	DEF14A
Dr. James I. Healy	5.27%	DEF14A
Thomas Gad	3.05%	DEF14A
Michael Rossi	0.77%	DEF14A
Dr. Ashutosh Tyagi	0.27%	DEF14A
David N. Gill	0.26%	DEF14A
Laura J. Hamill	0.20%	DEF14A
Peter Pfreundschuh	0.13%	DEF14A
Dr. Mary Tagliaferri	0.07%	DEF14A

Percentages above are of 43,882,638 shares outstanding, as reported by Y-mAbs Therapeutics, Inc. on its Form 10-Q dated April 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Y-mAbs Therapeutics, Inc.’s 10-Q dated April 30, 2024. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At Y-mAbs Therapeutics, Inc.'s shareholder meeting held July 11, 2025, in the 2025-2026 proxy season, 127 asset managers reported how they voted on 3 ballot items in their SEC Form N-PX filings, covering 488 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY VOTE BASIS, THE COMPENSATION OF THE COMPANY'S NAMED… — Y-mAbs Therapeutics, Inc.'s filing reports the proposal as approved, with 88% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Y-mAbs Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on July 15, 2025.

Y-mAbs Therapeutics, Inc. proxy season coverage: 2023-2024 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.